| 1611 |
ALIMABALOXAVIR |
BALOXAVIR MARBOXIL 20 MG |
TABLET |
BLISTERPACK |
TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 12 YEARS OF AGE OR OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 48 HOURS AND WHO ARE OTHERWISE HEALTHY |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
12 L 1272/24 |
2024-12-23 |
2029-12-22 |
View |
| 1612 |
ALIMODIPINE |
AMLODIPINE 10 MG |
TABLET |
BLISTERPACK |
PRIMARY HYPERTENSION, CHRONIC STABLE PECTORIS AND VARIANT ANGINA PECTORIS |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
12 L 1048/23 |
15-JAN-2024 |
14-JAN-2027 |
View |
| 1613 |
ALIPRATINIB |
PRALSETINIB 100 MG |
CAPSULE |
BOTTLE |
METASTATIC REAARANGED DURING TRANSFECTION FUSION POSITIVE NON SMALL CELL LUNG CANCER, RET mutant medullary thyroid cancer, RET fusion positive thyroid cancer |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
05 L 1102/24 |
27-MAY-2024 |
26-MAY-2027 |
View |
| 1614 |
ALIRUXOLITINIB |
RUXOLITINIB 20 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
04 L 1328/25 |
07-APR-2025 |
06-APR-2030 |
View |
| 1615 |
ALISALVEN |
SALBUTAMOL 2 MG |
TABLET |
BLISTERPACK |
USE TO ALLEVIATE SYMPTOMS OF BRONCHIAL ASTHMA OR ASTHATIC BRONCHITIS ACCOMPANIED BY BRONCHOSPAM |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
11 L 1230/24 |
14-NOV-2024 |
13-NOV-2029 |
View |
| 1616 |
ALISELINISO |
SELINEXOR 20 MG |
TABLET |
BOTTLE |
IN COMBINATION WITH BPRTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY, FOR THE TREATMENT OF ADULT PATIENT WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULLAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYTEMIC THERAPY |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
10 L 1223/24 |
31-OCT-2024 |
30-OCT-2029 |
View |
| 1617 |
ALISERPATINIB |
SELPERCATINIB 40 MG |
CAPSULE |
BOTTLE |
FOR THE TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON SMALL CELL LUNG CANCER WITH A REARRANGED DURING TRANSFECTION GENE FUSION |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
11 L 1233/24 |
14-NOV-2024 |
13-NOV-2029 |
View |
| 1618 |
ALITADA |
TADALAFIL 20 MG |
TABLET |
BLISTERPACK |
ERECTILE DYSFUNCTION, BENIGN PROSTATIC HYPERPLASIA |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
10 L 1030/23 |
26-OCT-2023 |
25-OCT-2026 |
View |
| 1619 |
ALITRAMETINIB |
TRAMETINIB DIMETHYL SULOXIDE 2 MG |
TABLET |
BOTTLE |
FOR THE TREATMENT OF BRAF INHIBITOR TREATMENT -NAIVE PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATION |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
11 L 1256/24 |
25-DEC-2024 |
24-DEC-2029 |
View |
| 1620 |
ALIUPATINIB |
UPADACITINIB 15 MG |
TABLET |
BOTTLE |
MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS, ACTIVE PSORIATIC ARTHRTIS, MODERATE TO SEVERE ULCERATIVE COLITIS, MODERATE TO SEVERE CHROHN'S DISEASE, ACTIVE ANKYLOSING SPONDYLITIS |
NULL |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY |
LAOS |
CERTIFICATE RELEASED |
11 L 1260/24 |
25-DEC-2024 |
24-DEC-2029 |
View |
